Last checked at 6 Feb 2017 12:47
Notification of major interests in shares
LONDON, 6 February 2017 - Hikma Pharmaceuticals PLC ("Hikma") (LSE: HIK) (DIFX: HIK), the fast growing multinational pharmaceuticals group, announces as follows:
1 | Identity of the issuer or the underlying issuer of existing shares to which the voting rights are attached | Hikma Pharmaceuticals PLC
|
2 | Reason for the notification | |
An acquisition or disposal of voting rights | Yes | |
An acquisition or disposal of financial instruments which may result in the acquisition of shares already issues to which voting rights are attached | No | |
An event changing the breakdown of voting rights | No | |
Other (please specify): Compliance with the Transparency Directive | No |
3 | Full name of the person subject to the notification obligation | The Capital Group Companies, Inc. | ||||||
4 | Full name of shareholders | Refer to section 9 | ||||||
5 | Date of the Transaction (and date on which the threshold crossed is reached differently) | 1 February 2017 | ||||||
6 | Date on which the issuer notified | 3 February 2017 | ||||||
7 | Threshold that is crossed | 10% | ||||||
8 | Notified details | See A, B & C below | ||||||
A. Voting rights attached to shares | ||||||||
Class type of shares (if possible using the ISIN code) | Situation previous to the triggering transaction | Resulting situation after the triggering transaction | ||||||
Number of shares | Number of voting rights | Number of shares | Number of voting rights | % of voting rights | ||||
Direct | Direct | Indirect | Direct | Indirect | ||||
Ordinary Shares (0.10 GBP) GB00B0LCW083 | 22,321,334 | 22,321,334 | 24,161,334 | 10.0691% | ||||
B. Qualifying Financial instruments | ||||
Resulting situation after the triggering transaction | ||||
Type of financial instrument | Expiration Date | Exercise/Conversion Period/Date | Number of voting rights that may be acquired if the instrument if exercised/converted | % of voting rights |
- | - | - | - | - |
C: Financial Instruments with similar economic effect to Qualifying Financial Instruments | ||||||
Resulting situation after the triggering transaction | ||||||
Type of financial instrument | Exercise Price | Expiration Date | Exercise/Conversion Period/Date | Number of voting rights instrument refers to | % of voting rights | |
Nominal | Delta | |||||
- | - | - | - | - | - | - |
Total A+B+C | |
Number of Voting rights | % of voting rights |
24,161,334 | 10.0691% |
9 | Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable | |||||||||||||||||||||||||
| ||||||||||||||||||||||||||
Proxy Voting | ||
10 | Name of the proxy holder | N/A |
11 | Number of voting rights proxy holder will cease to hold: | |
12 | Date on which proxy holder will cease to hold voting rights: | |
13 | Additional Information | |
14 | Contact name: | Christopher Aquino |
15 | Contact telephone number: | +001 (213) 615-0469 |
- ENDS -
About Hikma
Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based primarily in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe. In 2015, Hikma achieved revenues of $1,440 million and profit attributable to shareholders of $252 million.